Clinical Trials in New York State

Showing 10501-10520 of 13,041 trials

A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C

NCT01087944

This randomized, cross-over, open label study will compare the tolerability and handling of application of peginterferon alfa-2a \[Pegasys\] by autoinjector versus pre-filled syringe in patients with chronic hepatitis C, either on treatment with peginterferon alfa-2a for at least 12 weeks or treatment-naïve for peginterferon alfa-2a. Patients will be randomized to self-injection of 180mcg peginterferon alfa-2a once a week using either an autoinjector or a prefilled syringe for 3 weeks, then switch to use the other method of injection for another 3 weeks. Anticipated time on study treatment is 6 weeks. Target sample size is \<100 patients.

Hepatitis C, Chronic

Hoffmann-La Roche60 participantsStarted Mar 2010

Los Angeles, California, United States • Bradenton, Florida, United States • Orlando, Florida, United States +9 more locations

COMPLETEDPhase 369 miles

Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients

NCT01114737

This double-blind, placebo-controlled, randomized study is designed to evaluate the safety and therapeutic effects of sapropterin dihydrochloride on neuropsychiatric symptoms in subjects with PKU.

Phenylketonuria

BioMarin Pharmaceutical206 participantsStarted Aug 2010

La Jolla, California, United States • Los Angeles, California, United States • Palo Alto, California, United States +33 more locations

A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C

Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients

Find Trials by Condition in New York State

Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months

The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine

Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

AqueSys Microfistula Implant in Refractory Glaucoma

Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis

TearLab Refractive Surgery Dry Eye Study

Study of Renal Denervation in Patients With Heart Failure

Re-Evaluating the Inhibition of Stress Erosions: Gastrointestinal Bleeding Prophylaxis In ICU

A Novel Diet-Phenotype Interaction Affecting Body Weight

Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis

Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome